PharmacoDesign Purchases Illumina Genotyping Solutions for Pharmacogenomics Research
News Oct 27, 2005
Illumina, Inc. has announced an agreement of sale with PharmacoDesign (PD) for a BeadStation system and whole-genome genotyping arrays and reagents for ongoing pharmacogenomics studies.
PharmacoDesign will genotype various Korean populations with the aim of understanding genetic variation andpersonalizing treatment foroptimal clinical outcomes. Under the agreement, Illumina will gain access to biomarkers discovered by PD and will be able to incorporate such markers into proprietary SNP panels under a worldwide, royalty-bearing exclusive license.
PD will study diseases that include obesity, cancer and allergy-induced reactions such as atopy. The company works in partnership with large Korean hospitals to prescribe individualized treatments that utilize diet and "functional foods" in addition to traditionalpharmacological approaches. Initially, PD will utilize Illumina's Sentrix® Human-1 BeadChip, which contains over 100,000 SNP markers, 70% of which are located in or very near genes for direct disease association studies.
The Human-1 is powered by Illumina's Infinium™ assay, which allows investigators to query the entire genome with call rates, reproducibility and related performance metrics comparable to Illumina's GoldenGate® assay protocol, a gold standard of the HapMap Project. The Infinium assayenables virtually unconstrained, intelligent SNP selection for BeadChip array content.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE